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Phillip DeFedele
DATA PROTECTION IN CLINICAL TRIALS : ADAPTING EU SOLUTIONS TO US RESEARCH
I.

Introduction

Clinical trials are the primary basis upon which the U.S. Food and Drug Administration
(FDA) determines whether there is substantial evidence to support efficacy claims of new drugs
as well as whether such drugs are safe. 1 Clinical trials are studies in which human subjects are
administered a new drug and they constitute a substantial part of the entire research and
development process and are essential in order to obtain FDA approval of a new drug. 2 Clinical
trials take, on average, six to seven years to complete out of a total of ten to fifteen years for
research and development.3 Thousands of patients may be enrolled in clinical trials through all
three phases and, consequently, there are many actors involved in the conduct of such studies.4
Due to the increasing presence of these many different actors involved in such trials, data
obtained from those enrolled in the study must be transferred to and from these various actors. 5
These particular transfers of data in the course of a single clinical trial are the subject of this
paper.
Data collected from clinical trials are entitled to special legal protections in order to
safeguard the confidentiality and privacy of the human subjects involved in such research. In the
United States, such protections are set forth in the Common Rule as well as FDA regulations,
both of which contain additional safeguards for human subjects involved in research. 6 In the
European Union (EU), the colloquially known Data Privacy Directive, which broadly applies to
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21 C.F.R. § 314.126.
Id.
3 PHRMA, 2013 PROFILE BIOPHARMACEUTICAL RESEARCH INDUST RY 32, 34 (2013).
4 Id.
5 See infra Part II.C.
6 45 C.F.R. § 46.101 et seq.; see, e.g., 21 C.F.R. pt. 50 & 56.
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all forms of personal data, provides for the protection of data that result from clinical trials. 7 As
the times and technology change so must regulations and, consequently, the U.S. Department of
Health and Human Services (HHS) has decided to amend the Common Rule to strengthen,
among other things, the protection of data obtained from human subject research. 8
The HHS is seeking to apply requirements from another piece of U.S. legislation, the
Health Insurance Portability and Accountability Act (HIPAA), to the Common Rule in order to
provide the standards under which the privacy of research data will be protected. 9 Instead of
looking domestically, however, it may benefit the HHS, and ultimately the human subjects
protected by the Common Rule, to examine non-U.S. methods of data protection, namely the
Data Protection Directive, in crafting its own new protections. Ultimately, when it comes to the
protection of research data from human subject research, there must be a balance between the
interests of providing notice to and protecting the data of human subjects and ensuring that
research may occur unhindered in order to encourage innovation and allow new therapies to
reach the market as soon as possible. This policy of balancing such interests underlies this paper
and ultimately guides the arguments made herein. Part II of this paper shall provide a brief
history of human subject research protections, a brief overview of emerging technologies that
may be the impetus for revising data protection policies, and an overview of the ANPRM as well
as its relevance to FDA regulations and the actors involved in clinical research. Part III will
provide an overview of the HIPAA standards that may be incorporated into the Common Rule
and how they will apply to clinical trial research. Part IV will explain the applicable legal
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Directive 95/46/EC, of the European Parliament and of the Council of 24 October 1995 on the Protection of
Individuals with regard to the Processing of Personal Data and on the Free Movement of such Data, 1995 O.J. (L
287/31) [hereinafter “Data Protection Directive”].
8 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay,
and Ambiguity for Investigators, 76 Fed. Reg. 143, 44515 (proposed July 26 2011) [hereinafter “ANPRM”].
9 Id. at 44526.
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framework under the Data Protection Directive as it would apply to clinical trials in the EU. Part
V shall compare and contrast HIPAA and the Data Protection Directive with regards to research
and advocate that the Data Protection Directive provides the best balance of the aforementioned
policy interests. Lastly, Part VI concludes the paper.
II.

A.

Evolution of Human Subject Research Protections, Data Protection Concerns in
Emerging Technologies, and Regulatory Schemes
Evolution of Human Subject Research Protections
Prior to World War II, there was no international statement of ethical principles that

should govern human experimentation. 10 Protections for human subjects originated from the
Nuremberg Code11 which resulted from the Doctors’ Trial in which Nazi doctors were put on
trial for experiments carried out in concentration camps. The Nuremberg Code set forth ten
principles pursuant to which research should be conducted.12 The most influential early
document on human subject research protections, however, is the World Medical Association’s
Ethical Principles for Medical Research Involving Human Subjects 13 , more commonly referred
to as the Declaration of Helsinki. 14 The Declaration of Helsinki was developed by the World
Medical Association (WMA) as “a statement of ethical principles for medical research involving
human subjects, including research on identifiable human material and data.”15 The Declaration
of Helsinki has been amended since its initial adoption in June of 1964 and contains general
principles as well as special attention to, among other things, vulnerable populations, risks and

Delon Human & Sev Fluss, The World Medical Association’s Declaration of Helsinki: Historical and
Contemporary Perspectives 4 (July 24, 2001),
http://www.wma.net/en/20activities/10ethics/10helsinki/draft_historical_contemporary_perspectives.pdf.
11 The Nuremberg Code, U.S. Department of Health & Human Services (last visited Oct. 10 2014),
http://www.hhs.gov/ohrp/archive/nurcode.html.
12 Id.
13 Declaration of Helsinki, June 1964.
14 Human, supra note 10, at 2.
15 Declaration of Helsinki.
10
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benefits, protocols, ethics committees, and informed consent. 16 The Declaration of Helsinki also
contains a principle concerning privacy and confidentiality which declares that “[e]very
precaution must be taken to protect the privacy of research subjects and the confidentiality of
their personal information.”17 Thus, even before the advent of modern technological advances,
the privacy of individuals was already a concern on an international level.
In the United States, the National Research Act of 1974 established the National
Commission for the Protection of Human Subjects of Biomedical and Behavioral Research
(“National Commission”), which was tasked with identifying the basic ethical principles that
should guide the conduct of research involving human subjects. 18 In doing so, the National
Commission produced the Belmont Report which summarizes the basic ethical principles for
conducting human subject research. 19 The National Commission set forth three principles in the
Belmont Report: (1) respect for persons; (2) beneficence; and (3) justice. 20 The principle of
respect for persons encompasses the requirement to acknowledge autonomy and the requirement
to protect those with diminished authority. 21 The principle of beneficence is an obligation to do
no harm and maximize possible benefits while minimizing possible harms. 22 The final principle
of justice is a sense of fairness in distribution and that equals should be treated equally.23 Most
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Id.
Id.
18 The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The
Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research , Apr. 18, 1979
[hereinafter “The Belmont Report”].
19 Id.
20 Id.
21 Id.
22 Id.
23 Id.
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significantly, the Belmont Report influenced the United States’ human subject regulations
resulting in both the HHS and the FDA revising their respective human subject regulations.24
The preeminent federal regulations regarding human subject research are embodied in the
Common Rule which was first published in 1991 by the HHS.25 The Common Rule applies to all
research involving human subjects that is conducted or supported, meaning funded in whole or in
part, by a federal department or agency.26 A human subject is defined as a “living individual
about whom an investigator . . . conducting research obtains . . . [d]ata through intervention or
interaction with the individual, or . . . [i]dentifiable private information.”27 Under the Common
Rule, research is defined broadly as “a systematic investigation, including research development,
testing and evaluation, designed to develop or contribute to generalizable knowledge.”28 The
Common Rule goes on to explain that an intervention may be a physical procedure by which data
are gathered or manipulations of the subject, or his or her environment, performed for research
purposes.29 Moreover, an interaction may be a communication or interpersonal contact between
the investigator and subject.30 Given the collection of data involved in research, the Common
Rule also addresses the concept of private information. 31
Private information under the Common Rule includes information about “behavior that
occurs in a context in which an individual can reasonably expect that no observation or recording
is taking place, and information which has been provided for specific purpose by an individual

Federal Policy for the Protection of Human Subjects (‘Common Rule’) , U.S. DEPART MENT OF HEALTH & HUMAN
SERVICES (last visited Nov. 17, 2014), http://www.hhs.gov/ohrp/humansubjects/commonrule/.
25 Id.
26 45 C.F.R. § 46.101.
27 45 C.F.R. § 46.102(f).
28 45 C.F.R. § 46.102(d).
29 Id.
30 Id.
31 Id.
24
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and which the individual can reasonably expect will not be made public.”32 Moreover, private
information must be individually identifiable, meaning that “the identity of the subject is or may
readily be ascertained by the investigator or associated with the information”, in order for the
ascertainment of such information to be considered research involving human subjects. 33 Despite
the attention given to defining private information, the Common Rule simply places the burden
on institutional review boards (“IRBs”) to be responsible for protecting the privacy of subjects
and data.34 Specifically, an IRB must determine that, among other things, there are “adequate
provisions to protect the privacy of subjects and to maintain the confidentiality of data” prior to
approving research.35 Although this provision may have been appropriate when the Common
Rule was originally promulgated in 1991, the advent of new technologies resulting in increased
informational risks requires more robust protections.36
B.

Data Protection Concerns in Emerging Technologies
There are increasing uses of genetic information, biospecimens, and databases in research

that result in informational risks, meaning risks of inappropriate uses or disclosures of human
subjects’ information.37 Wrongful disclosures, such as those relating to substance abuse or
chronic illness, may have practical adverse effects on a particular research subject, including
jeopardizing employment and causing emotional and social harms. 38 Two types of research
techniques that incite such risks are bioinformatics and functional genomics.39

32

Id.
Id.
34 45 C.F.R. § 46.111(a)(7).
35 Id.
36 ANPRM, supra note 8, at 44513–44514.
37 Id.
38 Id. at 44516.
39 YALI FRIEDMAN, BUILDING BIOT ECHNOLOGY : BIOT ECHNOLOGY BUSINESS, REGULAT IONS, PAT ENTS, LAW , POLICY
AND SCIENCE 41, 46 (2014).
33
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Bioinformatics applies information technology to manage and analyze research data,
which assists scientists in managing and interpreting such data.40 Bioinformatics utilizes
computers to assist in data management which permits the collection and analysis of biological
information,

including

deoxyribonucleic

acid

(DNA)

sequencing.41

The

advantage

of

bioinformatics is the ability to extract information and detect certain patterns from large
databases.42 Bioinformatics is also able to analyze masses of information and allow comparative
analyses.43 Clearly, the ability to access and analyze large databases is susceptible to
informational risks of improper disclosure or uses.
Functional genomics focuses on gene activity in both healthy and diseased states, which
allows analyses of how genetic variations may account for different levels of efficacy of a drug
in certain populations.44 Specifically, pharmacogenetics studies how genetic differences affect
how people respond to drugs in order to understand variations between drug targets and enzymes
that affect efficacy and toxicity.45 This technique allows researchers to develop drugs that are
capable of addressing the effects genetic variations may have on safety and efficacy.46
Pharmacogenetics rely upon analyses of individuals’ genetic information, which is certainly the
most unique and personal information about an individual, and, therefore, must have adequate
privacy protections in place.
All in all, these emerging research technologies must be subject to adequate data
protections in order to not only ensure that such data is protected, but also to make sure that such

40

Id. at 41–42.
Id. at 42.
42 Id. at 43.
43 Id.
44 Id. at 46.
45 Id. at 47.
46 Id. at 48.
41
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data is seen to be protected by regulators and subjects. 47 Although one can argue that stringent
protections may hinder research, the fact remains that research depends upon voluntary
contribution and, therefore, if subjects were to lose faith in the safeguards in place to protect their
data, it would have an adverse effect on their willingness to participate, which would impede
new research.48 Therefore, adequate privacy protections are not only necessary for the protection
of human subjects but are also necessary to ensure the continued success of research and the
utilization of new research techniques.
C.

From the Common Rule to FDA Regulations
As further discussed below, the HHS in its ANPRM seeks to modify, among other things,

the protection of data obtained from human subjects in the Common Rule. 49 The Common Rule,
however, only applies to research that is either conducted or financially supported by a federal
agency.50 Therefore, absent such agency involvement, the Common Rule does not apply to a vast
amount of research undertaken to achieve FDA approval of a new pharmaceutical product since
they are typically privately funded by the sponsor.51 Such studies, however, are governed by
FDA regulations codified in Title 21 of the Code of Federal Regulations. 52 Although research
using federal funding and those for FDA approval are governed by different regulatory regimes,
both sets of regulations stem from the same ethical foundation, specifically the Belmont

47

M ARK TAYLOR, GENET IC DAT A AND T HE LAW : A CRIT ICAL PERSPECTIVE ON PRIVACY PROT ECTION 5 (Margaret
Brazier et al. eds., 2012).
48 Id.
49 ANPRM, supra note 8, at 44513–44514.
50 45 C.F.R. § 46.101.
51 Although it is often the case that pharmaceutical companies entirely fund their own research, an example of an
exception to this is when a pharmaceutical company receives funding from the Biomedical Advanced Research and
Development Authority (BARDA). See, generally, Biomedical Advanced Research and Development Authority –
PHE, PUBLIC HEALT H EMERGENCY (last visited Nov. 22, 2014),
http://www.phe.gov/about/barda/Pages/default.aspx.
52 See, e.g., 21 C.F.R. 56.101 et seq.
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Report.53 Thus, respect for persons, beneficence, and justice, the three ethical principles laid out
in the Belmont Report, are equally applicable to both the Common Rule and FDA regulations
governing human subject research.
A more concrete example of this connection is the nearly identical language contained in
both the Common Rule and FDA regulations. 54 Like under the Common Rule, an IRB
overseeing research subject to FDA regulations must ensure, among other things, that there are
“adequate provisions to protect the privacy of subjects and to maintain the confidentiality of
data” in order to approve the research study.55 This is the exact same language contained in the
Common Rule’s section concerning IRB approval of research. 56 Given these strong parallels in
origins and language, the considerations involving the reformation of the Common Rule should
also apply to FDA regulations. In fact, because the Common Rule is only limited to studies
receiving federal funding, there is a more urgent need to amend the FDA regulations given the
vast amount of subjects involved and studies.57 Therefore, the revisions to the Common Rule and
recommendations contained herein should apply and encourage equivalent modifications to the
FDA regulations.
As discussed further below, these revisions to the Common Rule were partially motivated
by the increase in the amount of actors involved in the conduct of clinical trials. For starters,
there is the sponsor, which, in most instances, is the pharmaceutical company seeking approval
for its new drug.58 The sponsor initiates and maintains ultimate responsibility for a clinical trial. 59
A sponsor’s obligations include, among other things, selecting investigators, monitoring the

53

See supra note 24.
Compare 45 C.F.R. § 46.111(a)(7) with 21 C.F.R. § 56.111(a)(7).
55 21 C.F.R. § 56.111(a)(7).
56 Compare 45 C.F.R. § 46.111(a)(7) with 21 C.F.R. § 56.111(a)(7).
57 See supra Part I.
58 21 C.F.R. § 312.3.
59 Id.
54
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investigations, and ensuring that the study is conducted in accordance with the protocol. 60 The
sponsor may, however, delegate its responsibilities regarding the conduct of a study to a contract
research organization (CRO).61 In such an instance, the CRO would be the middle man between
the sponsor and any clinical trial sites. Moreover, each site where the clinical trial is taking place
has a principal investigator that leads the conduct of the study as well as a study team made up of
various personnel.62 Additionally, depending upon the nature of the clinical trial, the sponsor
may utilize a Data Safety Monitoring Board (DSMB) to review the un-blinded data from the
clinical trial in order to evaluate the safety of trial subjects and the validity and scientific merit of
the trial.63 Thus, these various actors that, in part, spurred the HHS to revise the Common Rule
further demonstrate the vast amounts of data transfers that occur in conducting clinical trials
which must be subject to heightened data protection standards.
D.

Advanced Notice of Proposed Rulemaking
The HHS released the ANPRM in order to address the drastically changed landscape of

research since the Common Rule’s enactment in 1991 and to comply with the President’s
Executive Order requiring federal agencies to review their respective regulations in order to
make such regulatory schemes more effective and less burdensome.64 The HHS explains that, not
only have research techniques changed, but also that many actors, in addition to the sponsor and
principal investigators, have joined the research enterprise. 65 In the ANPRM, the HHS notes that
there are doubts as to whether the current regulatory framework is sufficient for the protection of

60

21 C.F.R. § 312.50.
21 C.F.R. § 312.23.
62 BAKER & M CKENZIE , CLINICAL TRIALS A GLOBAL HANDBOOK 617 (2010).
63 FDA, OMB CONT ROL NO. 0910-0581, GUIDANCE FOR CLINICAL TRIAL SPONSORS: EST ABLISHMENT AND
OPERAT ION OF CLINICAL TRIAL DATA M ONITORING COMMITTEES (2006).
64 Exec. Order No. 13,563 (2011); ANPRM, supra note 8, at 44513.
65 ANPRM, supra note 8, at 44513.
61
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human subjects.66 The ANPRM seeks to amend the Common Rule to alleviate concerns about its
adequacy in protecting human subjects and to respond to criticisms of the Common Rule related,
to among other things, IRB review of research, informed consent, and increasing informational
risks.67 As part of this overhaul, the ANPRM seeks to impose HIPAA standards for the
protection of data in order to remedy the increased informational risks that are present in human
subject research.68 The ANPRM urges that the current Common Rule approach requiring IRBs to
evaluate informational risks may not be the best methods of minimizing such risks due to a
potential lack of expertise regarding data protection. 69 The ANPRM proposes to apply
mandatory data standards as set forth under HIPAA to apply to all data that are collected,
generated, stored, or used in human subject research. 70 Therefore, the ANPRM seeks to enforce
standards for the protection of data based on those set forth in HIPAA in all research studies
governed by the Common Rule.71
III.

HIPAA

Congress enacted HIPAA in 1996 in order to, among other things, improve the portability
and continuity of health insurance coverage, and to combat waste, fraud and abuse in the health
insurance and health care delivery systems. 72 The HHS had the responsibility to promulgate
regulations

regarding the privacy of individuals’ health information. 73

These regulations

encompass the HIPAA Privacy Rule, which is meant to assure that individuals’ health
information is protected while allowing such information to be transmitted in order to promote

66

Id.
Id. at 44513–44514.
68 Id.
69 Id. at 44516.
70 Id.
71 Id. at 44526.
72 Pub. L. 104-191.
73 U.S. DEPART MENT OF HEALTH AND HUMAN SERVICES, SUMMARY OF T HE HIPAA PRIVACY RULE 1 (2003).
67
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high quality healthcare.74 The HIPAA Privacy Rule only applies to “covered entities” which are
defined as health plans, healthcare clearing houses, and healthcare providers. 75 A healthcare
provider may be a person or entity that provides, bills for, or is paid for healthcare in the normal
course of business.76 Although HIPAA mainly protects medical records and other related data
used in providing and reimbursing healthcare and a pharmaceutical manufacturer is not a
covered

entity,

the Privacy Rule already applies to research in a limited manner.77

Pharmaceutical manufacturers must utilize hospitals and physicians in order to conduct clinical
trials.78 Hospitals and practicing physicians that are not solely involved in the conduct of
research fit the statutory definition of a healthcare provider under HIPAA.79 Therefore, when
interacting with patients on an individual site level, the principal investigator, institution, and
members of the study team that constitute covered entities are already bound by the provisions of
HIPAA. Under the ANPRM, however, the concept of a covered entity is essentially moot
because HIPAA privacy standards would apply to all actors involved in the clinical trial that are
handling protected health information. 80
Under HIPAA, covered entities are broadly prohibited from using or disclosing protected
health information except when permitted to do so, such as pursuant to a valid authorization.81
Protected health information (PHI) is defined as “individually identifiable health information”
that is transmitted or maintained in any form or medium.82 Individually identifiable health
information is a subset of health information that identifies the individual or with respect to

74

Id.
45 C.F.R. § 160.103.
76 Id.
77 Id.
78 See supra Part I.
79 45 C.F.R. § 160.103.
80 ANPRM, supra note 8, at 45516.
81 45 C.F.R. § 164.502(a).
82 45 C.F.R. § 160.103.
75
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which there is a reasonable basis to identify the individual from such information. 83 Health
information is defined as “any information . . . whether oral or recorded in any form or medium,
that: “[among other things,] relates to the past, present, or future physical or mental health or
condition of an individual.”84 The concept of PHI also applies to individuals that have been
deceased for 50 years or less.85 Although such data is considered PHI, it may be disclosed and
used under HIPAA provided such use or disclosure is solely for research, documentation of the
death of the individual is provided, and such use or disclosure is necessary for the research. 86
In the context of clinical trials, any data obtained from the subjects would constitute
“health information” under HIPAA as they would relate to the health or condition of an
individual and the drug’s effect on his or her health or condition. HIPAA, however, only applies
to individually identifiable health information and, therefore, if the information is properly deidentified, it is not subject to HIPAA protections. 87 Thus in the context of clinical research, if a
principal investigator were to de-identify any data collected from a research subject, he or she
may freely transmit it to any entity, such as the sponsor or CRO.
It is no easy task to de-identify data, however. There are two methods by which data can
be de-identified.88 First, an expert with expertise in statistical and scientific principles and
methods for identification may de-identify the data by applying such principles and methods and
subsequently determine that the risk for re-identification is very small.89 Second, specific
identifiers must be removed from the data related to, not only the individual, but also any
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45 C.F.R.
45 C.F.R.
85 Id.
86 45 C.F.R.
87 45 C.F.R.
88 45 C.F.R.
89 45 C.F.R.
84

§ 160.103.
§ 160.103 (2013).
§ 164.512(i)(1)(iii).
§ 164.502.
§ 164.514(b).
§ 164.514(b)(1).
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relatives, employers, or household members of the individual. 90 The identifies are names,
geographic subdivisions smaller than a state, all elements of dates except year (in most
instances), telephone and fax numbers, e-mail addresses, social security numbers, medical record
numbers, health plan beneficiary numbers, account numbers, certificate and license numbers,
vehicle identifiers and serial numbers, device identifiers and serial numbers, URLs, IP addresses,
biometric identifiers, full face images, and any other unique identifiers. 91 In order to qualify as
de-identified information under these two methods, the procedures set forth therein must be
strictly followed. Even limited data sets, which are discussed below, that have almost all
identifiers removed are still considered PHI and subject to the protections of HIPAA.92
Given the complexities of de-identifying data, there are two main methods by which data
could be transferred from one entity to another without having to be completely de-identified.
The first is through an authorization from the human subject and the second is through the use of
limited data sets.93 HIPAA clearly states that an entity may not use or disclose PHI without a
valid authorization, except as otherwise provided. 94 There are specific standards that an
authorization must meet in order to be considered valid. 95 First, there are certain core elements
that an authorization must fulfil which are a description of the information to be used in a
specific manner, the name of the person/entity authorized to make the disclosure, the name of the
person/entity to whom such information will be disclosed, a description of the purpose of such
disclosure, an expiration date or event upon which the authorization will expire, and the
signature of the individual and date.96 It is permissible for an authorization to not have an

90

45 C.F.R.
Id.
92 45 C.F.R.
93 45 C.F.R.
94 45 C.F.R.
95 45 C.F.R.
96 45 C.F.R.

§ 164.514(b)(2).

91

§ 154.514(e)(2).
§§ 164.508(a) & 164.514(d)(5)(e)(1).
§ 164.508(a).
§ 164.508(c).
§ 164.508(c)(1).
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expiration date when used for research purposes, including the establishment and maintenance of
research databases.97 In addition to these core requirements, an authorization must also make
certain statements that provide adequate notice to the individual of his or her right to revoke the
authorization in writing and any limitations thereon and the ability or inability to condition,
among other things, treatment on whether the individual signs the authorization. 98 Regarding the
revocation of an authorization, an individual is permitted by HIPAA to revoke a valid
authorization at any time in writing unless the authorized entity has acted in reliance thereon. 99
Lastly, an authorization must be written in plain language understandable by the research
subject.100
In addition to the standard authorization provisions described above, authorizations for
research purposes are able to be used for future research and combined with other forms, such as
the informed consent form for the study. As expressed by the HHS in the publication of the final
HIPAA Omnibus Rule, authorizations may be used for future research studies.101 An
authorization for future research purposes is valid so long as such future purposes are adequately
described so that “it would be reasonable for the individual to expect that his or her PHI could be
used or disclosed for such future research.”102 Although the HHS acknowledges that such
purposes could include specific statements, it does not require them. 103 It is important to note that
this does not require the subject to have actual knowledge of such other studies. In addition to
authorizing future research, research authorizations may be compounded with other documents

97

45 C.F.R. § 164.508(c)(1)(v).
45 C.F.R. § 164.508(c)(2)(i)–(ii).
99 45 C.F.R. § 164.508(b)(5)(i).
100 45 C.F.R. § 164.508(c)(3).
101 Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under the Health
Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act;
Other Modifications to the HIPAA Rules , 78 Fed. Reg. 17, 5612 (Jan. 25, 2013).
102 Id.
103 Id.
98
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in order to create a compound authorization. 104 Specifically, an authorization for research may be
combined with any other written permission regarding that particular study or another study. 105
This includes combining an authorization with an authorization for the creation and maintenance
of research databases or with the informed consent form to participate in the research.106
Although HIPAA authorizations are a straightforward and transparent means by which a human
subject’s data may be transferred from one actor in the clinical trial to another, there is another
means by which such data could be transferred without requiring the subject’s consent.
An entity may also use what HIPAA calls “limited data sets” to disclose data to a third
party without obtaining authorization from the data subject provided that the entity and the third
party enter into a data use agreement. 107 Limited data sets must be de-identified in a similar
manner to completely de-identified information although with less requirements.108 Similar to
complete de-identification, a limited data set must exclude certain direct identifiers of the
individual or of any relatives, employers, or household members of such individual. 109 The
identifiers are names, postal/street addresses, telephone and fax numbers, e-mail addresses,
social security numbers, medical record numbers, health plan beneficiary numbers, account
numbers, certificate and license numbers, vehicle identifiers and serial numbers, device
identifiers and serial numbers, URLs, IP addresses, biometric identifiers, and full face images. 110
As noted, this de-identification process differs from complete de-identification only in that
limited data sets may contain dates, political subdivisions smaller than a state, and do not broadly

104

45 C.F.R. § 164.508(b)(3)(i).
Id.
106 Id.
107 45 C.F.R. § 164.514(d)(5)(e)(1).
108 Compare 45 C.F.R. § 164.514(d)(5)(e)(2) with 45 C.F.R. § 164.514(b)(2).
109 45 C.F.R. § 164.514(d)(5)(e)(2).
110 Id.
105
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prohibit other unique identifiers.111 Limited data sets are only permitted to be used in a limited
number of circumstances, namely, for purposes of research, public health, or healthcare
operations.112
In order to disclose limited data sets without needing to obtain the individual’s
authorization, the disclosing entity must enter into a data use agreement with the recipient of
such information.113 The data use agreement is meant to obtain assurance that the recipient will
only use or disclose the data set for limited purposes.114 As with authorizations, however, data
use agreements must meet specific requirements. 115 A data use agreement must establish the
permitted uses and disclosures of the data set, set forth who is permitted to receive or use the
data set, and provide that the recipient will use and disclose the data only in accordance with the
agreement, use appropriate safeguards to prevent unauthorized uses or disclosures of the data set,
report to the disclosing entity any inappropriate uses or disclosures, ensure that any agents to
whom it provides such data agree to the same terms and conditions of the data use agreement,
and not identify or contact the individual. 116
In terms of research, a HIPAA authorization allows data to be transferred to another
entity without the need to significantly de-identify the information and enter into agreements
with such entities. Moreover, an authorization has several benefits in the context of research,
such as being able to be combined with the informed consent form and authorizing future
research. An authorization also more adequately balances the interests of notice and protection of
human subjects and uninhibited research, especially considering that limited data sets do not

111

See supra note 90.
45 C.F.R. § 164.514(d)(5)(e)(3)(i).
113 45 C.F.R. § 164.514(d)(5)(e)(4)(i).
114 Id.
115 45 C.F.R. § 164.514(d)(5)(e)(4)(ii).
116 Id.
112
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require notice to the subject. Importantly, a subject also has the opportunity to revoke an
authorization. Therefore, the HIPAA authorization will be the basis for comparison against the
EU legal framework for transferring data from one actor to another.
IV.

EU Data Protection

The EU has taken a very different approach to data protection from the United States and,
in fact, has explicitly established a right to data protection, which is considered a fundamental
right.117 The EU adopted Directive 95/46/EC 118 (the “Data Protection Directive” or the
“Directive”), more commonly known as the Data Protection Directive, in order to ensure that
“the level of protection of the rights and freedoms of individuals with regard to the processing of
personal data is equivalent in all Member States.”119 Unlike HIPAA, the Data Protection
Directive applies to all forms of “personal data” as defined in the directive. 120 The Data
Protection Directive applies to all 28 EU Member States 121 as well as non-EU Member States122
that are part of the European Economic Area (EEA). 123 It is important to note that the Data
Protection Directive acts as a framework which each individual Member State’s national laws
regarding data protection must follow.124 To parallel the U.S. regulatory scheme, the Directive
could be seen as the enabling statute which dictates the mission of an agency and purpose for
which it may promulgate regulations; whereas, the national laws would be the regulations

117

COUNCIL OF EUROPE ET AL ., HANDBOOK ON EUROPEAN DAT A PROT ECT ION LAW 20 (2014) [hereinafter
“Handbook”].
118 Directive, supra note 7.
119 Handbook, supra note 117, at 18.
120 Directive, supra note 7, at art. 1.
121 The 28 EU Member States are Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands,
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and United Kingdom.
122 The non-EU Member States are Iceland, Liechtenstein, and Norway.
123 Handbook, supra note 117, at 18.
124 Id.

18

implementing the statute. This paper will focus on the basic mechanism under the Directive that
permits the transfer of personal data from one actor in a clinical trial to another.125
The Data Protection Directive relies heavily on concepts of “personal data”, “processing
of personal data”, and consent in order to function. The Data Protection Directive makes a
blanket prohibition on the processing of personal data unless, among other legitimate legal bases,
the data subject has unambiguously given his or her consent.126 Moreover, not all personal data is
treated equally under the Data Protection Directive as there are additional protections for special
categories of personal data.127 Even for these special categories, however, consent is a valid basis
for processing such data provided it is made explicitly. 128
“Personal data” is defined as “any information relating to an identified or identifiable
natural person.”129 Such identified or identifiable persons are referred to as “data subjects.”130 An
identifiable person means that such person can be identified, directly or indirectly, which means,
in practice, that additional information capable of identifying the person can be acquired without
unreasonable effort.131 It is important to note that the Data Protection Directive only refers to
natural persons and, therefore, only natural persons are covered by its protections. 132 Moreover,
its protections only apply to living persons. 133 As previously mentioned, there are special
categories of personal data, known as “sensitive data”, which are subject to heightened
protections.134 Sensitive data include, among other things, data concerning health or racial or
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ethnic origin.135 In the context of clinical trials, the data gathered from the subjects regarding
their medical condition and the effects of the subject drug on such condition as well as any
genetic data collected constitute sensitive data and are subject to the heightened legal regime for
processing such data.
“Processing of personal data” means “any operation or set of operations which is
performed upon personal data, whether or not by automatic means.”136 Such means include, but
are not limited to, collection, recording, storage, use, disclosure by transmission, dissemination,
erasure, and destruction.137 It is clear that the concept of data processing is incredibly broad and
covers a wide variety of activities even those as simple as talking. 138 The aspect of processing of
personal data examined in the context of this paper is the transfer of personal data from one actor
to another in the setting of clinical trials. As already discussed, personal data may not be
processed absent a legitimate legal basis such as consent. The concept of consent; however, is
more than simply signing off on a request to process data as seen with HIPAA authorizations.
The Directive defines consent as “any freely given specific and informed indication of his
wishes by which the data subject signifies his agreement to personal data relating to him being
processed.”139 In order to be valid, however, the consent must fulfill the following elements: (1)
the data subject must have been under no pressure to consent; (2) the data subject must have
been informed of the object and consequences of consenting; and (3) the scope of consent must
be reasonably concrete.140 Regarding the second element, the data subject must have sufficient
information to make his or her decision, as determined on a case-by-case basis, in the form of a
135
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precise and easily understandable description of the subject matter, including the consequences
of consenting or the refusal to do so.141 The third element requires that the consent be specific as
determined by the “reasonable expectations of an average data subject.”142 If the processing
operations are to be changed or additional operations added in a way that could not reasonably
have been seen at the time of initial consent, the data subject’s consent must be obtained again. 143
Provided the consent process fulfills these three elements and is made explicitly, a data subject,
such as a human research subject, may have his or her sensitive data processed lawfully.144 There
is a general recognition of a data subject’s right to withdraw consent that he or she can exercise
at any time and at his or her discretion. 145 Moreover, a data subject is not required to give any
reason for the withdrawal and cannot be subject to adverse consequences as a result of such
withdrawal.146 There is a unique nuance to the withdrawal of consent, however. The withdrawal
of consent only applies to data processing to occur in the future, not that which has already
occurred.147 If there is no legal basis to justify the further storage of such data after the
withdrawal of consent, however, the data should then be deleted wherever such data is stored.148
Therefore, although the data subject consented to the initial collection of data, the storage of such
data is no longer permissible once consent is withdrawn and there is no additional legal basis for
further processing.
As a corollary to the consent process, personal data must be “collected for specified,
explicit and legitimate purposes and not further processed in a way incompatible with those
141
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purposes.”149 The entity that is processing the data must specify the purpose of the processing
and notify the data subject of such purpose prior to the processing of his or her data. 150 Echoing
the requirement that consent be specific, it is unlawful to process data for undefined or unlimited
purposes.151 For every new purpose, there must be a particular legal basis in order to process the
data for such purpose.152 Yet, if a new purpose is not incompatible with the initial purpose, the
data subject’s original consent may be a sufficient basis for the new purpose.153 In assessing
compatibility there are four key factors that must be considered: (1) “the relationship between the
purposes for which the data have been collected and the purposes of further processing”; (2) “the
context in which the data have been collected and the reasonable expectations of the data
subjects as to their further use”; (3) “the nature of the data and the impact of further processing
on the data subjects”; and (4) “the safeguards applied . . . to ensure fair processing and to prevent
any undue impact on the data subjects.”154 As an initial matter, this assessment should be carried
out by the entity processing data; however, in the event of litigation, the court would then
undertake this analysis.155
The first factor focuses on the substance of the relationship between the original purpose
and the purpose of further processing. 156 The relationship may cover situations where the further
processing was implied in the original purpose or situations where there is a partial or nonexistent link with the original purpose. 157 The greater the differences between the purposes, the
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more problematic it is for establishing compatibility. 158 The second factor involves the issue of
“what a reasonable person in the data subject’s situation would expect his or her data to be used
for based on the context of the collection.”159 Generally, the more unexpected or surprising the
further use is, the more it will be considered to be incompatible. 160 If the original collection of
the information was restrictive and specific, it is likely that there will be more limitations on
further use.161 Importantly, the relationship between the data subject and individual or entity
processing the data must be taken into account to determine whether there were inequalities in
bargaining power or coerciveness during the informed consent process. 162 If so, this factor will
weight against finding that the additional purpose is compatible with the original one.163
The third factor requires analysis of whether the further processing involves sensitive
data which require special protections. 164 If the information is sensitive, including medical and
genetic data, the scope for compatible uses is narrow. 165 Additionally, both positive and negative
consequences must be considered in determining the impact of further processing. 166 This
inquiry also includes an analysis of the way in which the data are further processed such as
processing by a third party and public disclosure or disclosure to a wide range of persons,
especially if unforeseeable at the time of data collection. 167
The final factor looks at the safeguards which are in place and may serve as a
counterbalance to any factors that weigh in favor of a finding of incompatibility. 168 The Working
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Party has suggested, however, that the first necessary step in ensuring compatibility is to respecify the purposes by providing additional notice to the data subjects and possibly allowing for
them to opt in or out.169 In some instances obtaining additional consent may be required. 170 All in
all, these factors are to be applied on a case-by-case basis and, therefore, there are no bright light
rules when it comes to determining compatibility. 171 Because of this fact-sensitive inquiry, it
may always be beneficial for one who is processing the data to keep the data subject informed in
order to ensure that they are on notice and have the ability to consent to any further processing.
This can easily be accomplished in clinical trials where researchers often follow up with subjects
after the administration of a new drug. Therefore, if the subject’s data needs to be transferred for
another purpose not contemplated in his or her original consent, it is possible to notify the
subject of such purpose and obtain consent.
As discussed, the Data Protection Directive allows personal data to be transferred from
one actor in a clinical trial to another by obtaining the subject’s informed consent which elevates
function over form and is an organic process encouraging constant communication between the
researcher and subject. Additionally, the purpose of the transfer must be concrete and cannot be
unlimited or undefined. Most significantly, a subject has the absolute right to revoke his or her
consent which requires the deletion of his or her personal data absent an additional legal basis for
the continued use or storage thereof. These key aspects of the Directive will be compared to
HIPAA.
V.

Similar Processes with Significant Differences

As a practical matter, HIPAA and the Data Protection Directive are relatively similar
regarding the ease of transferring data from one entity to another. Both regimes allow for the
169
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collection of a research subject’s permission to use and transfer his or her data to another party at
the initial time of contact, such as the informed consent process for participating in the trial.
HIPAA does this through obtaining a written and signed authorization; whereas, the Directive
achieves this through its own informed consent process. 172 Additionally, regardless of the
process, the research subject must be made aware of the purpose for which the data will be used
and who will use such data.173 Moreover, there are instances in which the research subject’s
consent may not be required in order to use the data, such as data sets and future research
authorizations for HIPAA and compatible purposes and certain secondary uses for the
Directive.174 There are, however, three significant differences between the regimes that, although
subtle in some regards, demonstrate that the Directive provides the best balance of protecting the
data of and notifying research subjects while unhampering research.
The first major difference is the informed consent process inherent in the Data Protective
Directive that is lacking in HIPAA. The Directive requires informed consent in order for data to
be collected, processed, and transferred between entities. 175 The consent process, similar to
informed consent for medical treatment, is reminiscent of an open dialogue between the data
subject and entity or individual obtaining and using such data.176 The data subject must give the
consent willingly and be made aware of the consequences of consenting and the concrete
purpose therefor.177 This is in stark contrast to HIPAA’s requirement of an authorization.
Although a HIPAA authorization must detail the purpose and who will use the data, HIPAA
merely sets forth the requirements that must be contained in an authorization and not which
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information should actually be communicated to the research subject.178 This is a significant
distinction between the two legal regimes. Provided that an authorization form contains the
necessary elements, the requirements in HIPAA are satisfied; whereas, in order for the
requirements of the Directive to be fulfilled, mere documentation is not sufficient as there must
be a kind of dialogue between the data subject and researcher. 179 Given the increased
informational risks today, ensuring that the research subject has a thorough understanding of the
use of his or her data, especially genetic data, is important. Moreover, this requirement further
ensures that researchers and those obtaining such data are adequately informing subjects.
Although this requirement may seem stringent and time-consuming, it best balances the
interest of providing notice to the subject and allowing research to occur unhindered. For
example, in the informed consent process, the data subject may be made aware of the purpose of
the collection of his or her data and the processing thereof as well as which entities will be using
the data.180 Therefore, where multiple actors are involved such as CROs, principal investigators,
and the sponsor, the connections between them can be made clear and, therefore, the data subject
may consent to the processing carried out by such entities.
The informed consent process’s advantages do not end there, however. Because the
process can be viewed as an ongoing dialogue, it has the possibility to permit other purposes for
processing data after initial consent has been obtained that would otherwise be incompatible and,
thus, impermissible. As already discussed, a mitigating factor in determining whether an
additional purpose is incompatible with the original purpose is notifying the data subject and, if
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necessary, obtaining further consent.181 Provided the data subject is able to be contacted, this is
only a slight inconvenience in comparison to the protections and notifications it provides.
The second major difference is the Directive’s limitations on the amount and types of
purposes for processing permissible under a single legal basis while HIPAA has the ability to
provide for future authorizations. Although it is a great step in the direction of streamlining and
simplifying processes involved in conducting research, HIPAA’s allowance of such future
authorizations does not truly provide research subjects with proper notice. Under HIPAA, the
research subject must be provided adequate notice, which need not contain any specific details,
so that the subject could reasonably foresee that his or her information could be used for further
research purposes.182 This is a very low burden to meet. So long as it is reasonably foreseeable
that a person’s data may be used for future research, which does not rely upon the subject’s
actual knowledge thereof, the authorization is valid. In reality, this means that a research subject
may have no idea in which studies their data are being used and would permit an unlimited
amount of uses and studies for which their data are used. While this surely helps encourage
research and simplifies the process for making research using such data possible, it completely
ignores the principle of providing notice to the research subject. Additionally, because the
research subject would not know the definite uses of his or her data, it would cause
complications with his or her ability to revoke the authorization. This is so because a research
subject may not have approved of a particular study or use of his or her data but, due to a lack of
actual knowledge of such study or use, they cannot revoke the authorization for future research.
This is a drastic difference between HIPAA and the Directive. Although the third element
of the informed consent process, which requires the scope of consent to be reasonably concrete,
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is judged by a similar standard of what the reasonable expectations of the average data subject
would be, it is compounded and strengthened by the requirement that purposes be specific and
concrete.183 Additionally, under this requirement, there is a blanket prohibition of processing
data for undefined or unlimited purposes. 184 Under this blanket rule, it is likely that an
authorization for future research under HIPAA would not survive such scrutiny. The true test,
however, is whether or not the additional purpose is compatible with the initial purpose of data
collection.
As already discussed, this is a fact-sensitive inquiry and there is no readily available
answer as to which further research purposes would be permissible and those that would not. 185
In the context of this paper, however, the focus is on clinical trials for drug approval and,
therefore, the purposes contained in the informed consent process would be tailored to the
particular clinical trial. Therefore, it is unlikely that future studies that are separate and apart
from the initial trial in which the subject participates would constitute compatible purposes,
especially considering the sensitive nature of the information. Even, for argument’s sake, if a
particular future purpose would be permissible under HIPAA and the Directive, the aspect of the
Directive that sets it above HIPAA in regards to this issue is that, of the factors to be considered
in evaluating compatible purposes, the fourth factor, which looks at safeguards in place, helps to
mitigate any adverse consequences of the further processing by encouraging the provision of
notice to the data subject and/or additional safeguards. 186 Thus, under the Directive, even if
consent is not required, there is a high likelihood that notice will be provided to the data subject,
so he or she can revoke consent in the event he or she disagrees with such purpose. Moreover, in
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the event the data subject cannot be reached due to death, the Directive no longer applies so
research will not be inhibited as a result of an occurrence out of the researchers’ hands, which is
similar to the exception provided in HIPAA.187 Therefore, once again, in regards to permitting
future research/processing, the Directive provides the best balance of providing notice and
protection to the data subject while allowing research to continue.
The third major difference is that the right to revoke is treated differently by the Directive
and HIPAA. The right to revoke is incredibly important in regards to data protection because it
allows the subject to ultimately have the final say in the use of his or her data. Thus, although
revocation of consent/authorization makes up a small part of both pieces of legislation, its
importance cannot be understated. As such, the distinctions between these legislative acts are
incredibly significant in evaluating the superiority of one over the other. The Data Protection
Directive, unlike HIPAA, provides an absolute right to revoke consent for data processing. 188
Although HIPAA does provide that a subject may revoke an authorization in writing, it permits
limitations to be set thereon as well as restricts this right if such authorization has been relied
upon.189 The Directive, on the other hand, contains an absolute right to revoke which is
accompanied by an obligation upon the entity processing the data to delete any collected data. 190
Because the data must be deleted if there is no further legal basis to retain the data, the data
subject is able to ensure that no further processing takes place by revoking his or her consent.
It is important to note that HIPAA protects against uses and disclosures of PHI and,
therefore, if an authorization is revoked it does not necessarily obligate the formerly authorized
entity to delete records of such data. Therefore, adequate protections must still be in place to
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ensure that such data is protected, which have the possibility of failing. The Directive, through its
implicit obligation on processors to delete data, however, provides the ultimate safeguard against
unlawful processing or disclosure. Additionally, on a personal level, it may give a data subject a
sense of relief knowing that his or her data is not just sitting stagnant in a database where there is
a real possibility of a data breach. All in all, the right to revoke embedded in the Directive is a
powerful tool to ensure that personal data is protected and processed for limited means. This
right of revocation, on its own, is substantial evidence of the better suited nature of the Directive
to handle sensitive information involved in clinical trials, especially genetic data.
The Directive through its informed consent process, limitations on purposes for which
data may be processed under a single legal basis, and right to revoke helps ensure that the
interests of notifying data subjects and protecting their data is equally balanced with the interest
of carrying out research unhindered. It is this equilibrium that makes the Directive a preferential
standard to HIPAA. Although HIPAA, in several respects, falls more on the side of encouraging
research, it does not adequately balance this beneficial effect with notification to individuals.
Additionally, the inherent limitations on the ability of an individual to revoke an authorization
under HIPAA are substantial disadvantages to employing this legal framework. All in all, the
Directive is the more appropriate approach to govern the protection of data in the context of
clinical trials.
VI.

Conclusion

It is clear that the current landscape of clinical trials is complex, and regulators must
account for both the safety and integrity of human subjects as well as encouraging innovation.
While these interests may seem to conflict, ultimately, ensuring that research subjects are
protected allows for their continued voluntary participation in research. Data protection is
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increasingly important in this modern age given new research technologies and the types of
personal information stored and used for research purposes. The HHS is correct in seeking to
revise the Common Rule at this time, but, more importantly, the FDA must follow suit in order
to ensure that the majority of research subjects involved in clinical trials for drug approvals can
benefit from increased data protections. The HHS’s proposal to rely upon mandatory HIPAA
privacy standards is admirable and a step in the right direction; however, as discussed, the EU
Data Protection Directive more adequately balances the relevant policy interests while protecting
human subjects’ data. Therefore, the HHS should look to this legal framework when it ultimately
decides to enact its reforms in order to ensure that human subjects are adequately protected from
information risks while allowing research to continue unhindered due to subjects’ willingness to
participate in new clinical trials because of such protections.
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